Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28347670 | 0.86 | GAA (0.34) | GAATP53MDM4ALDH1A1LMNA | |
| SCHEMBL2220319 | 0.83 | — | — | |
| SCHEMBL24358298 | 0.83 | — | — | |
| SCHEMBL10765697 | 0.83 | — | — | |
| SCHEMBL9428999 | 0.81 | — | — | |
| SCHEMBL9893089 | 0.79 | — | — | |
| SCHEMBL13861720 | 0.78 | — | — | |
| SCHEMBL13390980 | 0.78 | KMT2A (0.38) | GAAALDH1A1LMNAKDM4ERECQL | |
| SCHEMBL16918625 | 0.78 | — | — | |
| SCHEMBL29342177 | 0.78 | CETP (0.32) | GAATP53MDM4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012175513-A1 | THIENYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | claimed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11807851-B1 | Modified polynucleotides and uses thereof | ULTIMA GENOMICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023211710-A1 | METAL-FREE PROCESS FOR HYDROGEN PEROXIDE PRODUCTION | PORTLAND STATE UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230272221-A1 | REAGENTS FOR LABELING BIOMOLECULES | ULTIMA GENOMICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272221-A1 | REAGENTS FOR LABELING BIOMOLECULES | ULTIMA GENOMICS, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4200285-A1 | NEW ISOBUTYRYAMIDE DERIVATIVES, COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS CONTAINING SAID COMPOUNDS, AND THEIR USE FOR THE PROPHYLAXIS AND TREATMENT OF SENSIBLE, IN PARTICULAR INFLAMED SKIN OR INFLAMMATORY SKIN CONDITIONS | Beiersdorf AG (DE) | 2023-06-28 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-108884044-B | Piperidine derivatives | 大塚制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-4814352-A | ANTIDEPRESSANT CYCLOBUTYL BENZYLAMINE | THE BOOTS COMPANY PLC (GB) | 1989-03-21 | — | — | US | disclosed |
| US-4806570-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4767790-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | disclosed |
| US-4522828-A | CYCLOBUTYLALKYLAMINE COMPOUNDS, ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| US-4205169-A | N-[4-Azido-5-(2-ethoxyethyl)-6-phenyl-2-pyrimidinyl]acetamide and congeners | G. D. SEARLE & CO. (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272221-A1 | REAGENTS FOR LABELING BIOMOLECULES | POLRMT, TRMT1L, DUT | GAA 1804/4885TP53 2607/4885MDM4 871/4885 |
| US-11807851-B1 | Modified polynucleotides and uses thereof | PNKP, CPSF1, DCLRE1B | GAA 578/4885TP53 1210/4885MDM4 1379/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | GAA 279/4885TP53 4423/4885MDM4 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.